TABLE 2.
Comparison of properties of mDC derived from study subjects with those of mDC derived from a cohort of normal donors
| Subjects (n) | Mean (range)
|
|||
|---|---|---|---|---|
| Yield | Viability (%) | Purity (%) | IL-12 (pg/ml)b | |
| Study participants (18) | 9.1 × 107 (1.3 × 107-2.7 × 108) | 93 (69-99) | 100 (47a-100) | 347.7 (11-1,605)c |
| Uninfected volunteers (5) | 2.5 × 108 (2.3 × 108-3.5 × 108) | 90 (85-95) | 77 (75-89) | 270.0 (8-999)d |
a
In one subject, a second plastic adherence was required to increase purity as defined by positivity for CD86.
b
IL-12 production levels in DC supernatants were measured as described in Materials and Methods.
c
n = 15: three subjects had insufficient mature DC at the time of scheduled vaccination to permit IL-12 testing.
d
n = 1.